ID

18988

Description

A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00134706

Lien

https://clinicaltrials.gov/show/NCT00134706

Mots-clés

Versions (1)
  1. 28/11/2016 28/11/2016 -
Téléchargé le

28 novembre 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Prostate Cancer NCT00134706

Anglais

Eligibility Prostate Cancer NCT00134706

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically confirmed adenocarcinoma of the prostate
Description

Adenocarcinoma of prostate

Type de données

boolean

Alias
UMLS CUI [1]
C0007112
evidence of metastatic disease
Description

Neoplasm Metastasis Evidence of

Type de données

boolean

Alias
UMLS CUI [1,1]
C0027627
UMLS CUI [1,2]
C0332120
disease progression following androgen deprivation therapy
Description

Antiandrogen therapy | Disease Progression

Type de données

boolean

Alias
UMLS CUI [1]
C0279492
UMLS CUI [2]
C0242656
disease progression despite docetaxel-based chemotherapy
Description

Chemotherapy docetaxel Based | Disease Progression

Type de données

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C0246415
UMLS CUI [1,3]
C1705938
UMLS CUI [2]
C0242656
serum testosterone levels less than 50ng/ml (unless surgically castrated). patients must continue androgen deprivation with a luteinizing hormone-releasing hormone (lhrh) analogue if they have not undergone orchiectomy.
Description

Serum testosterone measurement | Male Castration | Antiandrogen therapy | Luteinizing Hormone-releasing Hormone Agonist | Orchiectomy

Type de données

boolean

Alias
UMLS CUI [1]
C0428413
UMLS CUI [2]
C0007347
UMLS CUI [3]
C0279492
UMLS CUI [4]
C1518041
UMLS CUI [5]
C0029189
no use of antiandrogens for at least 4 weeks
Description

Androgen Antagonists

Type de données

boolean

Alias
UMLS CUI [1]
C0002842
cancer and leukemia group b (calgb) performance status less than or equal to 2
Description

Cancer and Leukemia Group B performance status

Type de données

boolean

Alias
UMLS CUI [1,1]
C1516238
UMLS CUI [1,2]
C1518965
acceptable white blood cell (wbc), platelets, creatinine and ast counts
Description

White Blood Cell Count procedure | Platelet Count measurement | Creatinine measurement, serum | Aspartate aminotransferase measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0023508
UMLS CUI [2]
C0032181
UMLS CUI [3]
C0201976
UMLS CUI [4]
C0201899
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
significant peripheral neuropathy defined as grade 2 or higher
Description

Peripheral Neuropathy Significant CTCAE Grades

Type de données

boolean

Alias
UMLS CUI [1,1]
C0031117
UMLS CUI [1,2]
C0750502
UMLS CUI [1,3]
C1516728
within 4 weeks since completing external beam radiotherapy or 8 weeks since completing radiopharmaceutical therapy (strontium, samarium)
Description

External Beam Radiation Therapy Complete | radiopharmaceutical therapy Complete | Strontium | Samarium

Type de données

boolean

Alias
UMLS CUI [1,1]
C1517033
UMLS CUI [1,2]
C0205197
UMLS CUI [2,1]
C2094663
UMLS CUI [2,2]
C0205197
UMLS CUI [3]
C0038467
UMLS CUI [4]
C0036147
prior platinum-based chemotherapy (cisplatin or carboplatin) for hormone- refractory prostate cancer
Description

Chemotherapy Platinum-Based Hormone refractory prostate cancer | Cisplatin | Carboplatin

Type de données

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C1514162
UMLS CUI [1,3]
C1328504
UMLS CUI [2]
C0008838
UMLS CUI [3]
C0079083
concomitant chemotherapy, investigational agents or systemic steroids
Description

Chemotherapy | Investigational New Drugs | systemic steroids

Type de données

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C0013230
UMLS CUI [3]
C2825233
Retour au début de la page

Similar models

Eligibility Prostate Cancer NCT00134706

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Adenocarcinoma of prostate
Item
histologically confirmed adenocarcinoma of the prostate
boolean
C0007112 (UMLS CUI [1])
Neoplasm Metastasis Evidence of
Item
evidence of metastatic disease
boolean
C0027627 (UMLS CUI [1,1])
C0332120 (UMLS CUI [1,2])
Antiandrogen therapy | Disease Progression
Item
disease progression following androgen deprivation therapy
boolean
C0279492 (UMLS CUI [1])
C0242656 (UMLS CUI [2])
Chemotherapy docetaxel Based | Disease Progression
Item
disease progression despite docetaxel-based chemotherapy
boolean
C0392920 (UMLS CUI [1,1])
C0246415 (UMLS CUI [1,2])
C1705938 (UMLS CUI [1,3])
C0242656 (UMLS CUI [2])
Serum testosterone measurement | Male Castration | Antiandrogen therapy | Luteinizing Hormone-releasing Hormone Agonist | Orchiectomy
Item
serum testosterone levels less than 50ng/ml (unless surgically castrated). patients must continue androgen deprivation with a luteinizing hormone-releasing hormone (lhrh) analogue if they have not undergone orchiectomy.
boolean
C0428413 (UMLS CUI [1])
C0007347 (UMLS CUI [2])
C0279492 (UMLS CUI [3])
C1518041 (UMLS CUI [4])
C0029189 (UMLS CUI [5])
Androgen Antagonists
Item
no use of antiandrogens for at least 4 weeks
boolean
C0002842 (UMLS CUI [1])
Cancer and Leukemia Group B performance status
Item
cancer and leukemia group b (calgb) performance status less than or equal to 2
boolean
C1516238 (UMLS CUI [1,1])
C1518965 (UMLS CUI [1,2])
White Blood Cell Count procedure | Platelet Count measurement | Creatinine measurement, serum | Aspartate aminotransferase measurement
Item
acceptable white blood cell (wbc), platelets, creatinine and ast counts
boolean
C0023508 (UMLS CUI [1])
C0032181 (UMLS CUI [2])
C0201976 (UMLS CUI [3])
C0201899 (UMLS CUI [4])
Item Group
C0680251 (UMLS CUI)
Peripheral Neuropathy Significant CTCAE Grades
Item
significant peripheral neuropathy defined as grade 2 or higher
boolean
C0031117 (UMLS CUI [1,1])
C0750502 (UMLS CUI [1,2])
C1516728 (UMLS CUI [1,3])
External Beam Radiation Therapy Complete | radiopharmaceutical therapy Complete | Strontium | Samarium
Item
within 4 weeks since completing external beam radiotherapy or 8 weeks since completing radiopharmaceutical therapy (strontium, samarium)
boolean
C1517033 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
C2094663 (UMLS CUI [2,1])
C0205197 (UMLS CUI [2,2])
C0038467 (UMLS CUI [3])
C0036147 (UMLS CUI [4])
Chemotherapy Platinum-Based Hormone refractory prostate cancer | Cisplatin | Carboplatin
Item
prior platinum-based chemotherapy (cisplatin or carboplatin) for hormone- refractory prostate cancer
boolean
C0392920 (UMLS CUI [1,1])
C1514162 (UMLS CUI [1,2])
C1328504 (UMLS CUI [1,3])
C0008838 (UMLS CUI [2])
C0079083 (UMLS CUI [3])
Chemotherapy | Investigational New Drugs | systemic steroids
Item
concomitant chemotherapy, investigational agents or systemic steroids
boolean
C0392920 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
C2825233 (UMLS CUI [3])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial